AKSO Biopharmaceutical, a platform-based, clinical-stage biotech company, is leading the transformation of treatments for autoimmune diseases, oncology, fibrosis, and rare diseases. With a global focus, AKSO Bio is dedicated to delivering groundbreaking protein therapeutics for patients with critical unmet medical needs. Powered by its proprietary DEEP protein engineering platform, the company accelerates drug discovery, significantly reducing timelines and costs. AKSO Bio specializes in developing highly effective mono- and bispecific biologics, antibody-drug conjugates, and novel therapies. With a strong emphasis on target precision and exceptional therapeutic efficacy, AKSO Bio is poised to make a substantial impact on global healthcare.